Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06428617 · ClinicalTrials.gov registry record

Fundus Ablation Registry (Gastric Fundus Mucosal Ablation for Weight Loss)

A clinical trial of Obesity, sponsored by True You Weight Loss.

Recruiting
Registry status
200
Enrollment target
1
Study location

NCT06428617: Recruiting study of Obesity, sponsored by True You Weight Loss.

NCT06428617 is a study of Obesity that is actively recruiting participants, run by True You Weight Loss. The registered enrollment target is 200 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT06428617, a study of Obesity, is actively recruiting participants, sponsored by True You Weight Loss.

RECRUITING
Registry status
200 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to construct a multi-site, prospective registry to evaluate the clinical outcomes of patients who have undergone gastric fundus mucosal ablation at True You Weight Loss.

Primary Outcome

Measured percent change in total body weight over time following Gastric Fundus Mucosal Ablation. %TBWL = (pre-op weight - post op body weight) / (pre-op weight) \* 100 measured as a percentage.

Conditions Studied

Study Locations (1)

North Carolina

  • True You Weight Loss - Cary

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2024-06-01
Est. Completion 2028-06
True You Weight Loss

4 total trials

What NCT06428617 shows while recruiting

NCT06428617 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (76% lower).

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 0 interventions.

NCT06428617 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT06428617 about?

NCT06428617 is a clinical study titled "Fundus Ablation Registry (Gastric Fundus Mucosal Ablation for Weight Loss)". The purpose of this study is to construct a multi-site, prospective registry to evaluate the clinical outcomes of patients who have undergone gastric fundus mucosal ablation at True You Weight Loss.

What is the current status of trial NCT06428617?

This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2024-06-01. Estimated completion is 2028-06.

What conditions does trial NCT06428617 study?

This clinical trial studies the following conditions: Obesity.

Who is sponsoring clinical trial NCT06428617?

This trial is sponsored by True You Weight Loss, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06428617 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06428617's enrollment target sits among peer trials

200 315th of 1053 higher than 732 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06428617, the US trial registry maintained by the National Library of Medicine. NCT06428617 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.